SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Indications -- Cancer
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: keokalani'nui who wrote (24)4/17/2001 12:06:10 AM
From: Miljenko Zuanic  Read Replies (1) of 1840
 
ABX-EGF: a Fully Human Anti-EGF Receptor Antibody in Patients with Advanced Cancer.
Authors: Robert A. Figlin, Arie Belldegrun, Michelle E. Lohner, Lorin Roskos, Xiao-dong Yang, Gisela Schwab, Louis M. Weiner, UCLA School of Medicine, Los Angeles, CA; Abgenix, Inc., Fremont, CA; Fox Chase Cancer Center, Philadelphia, PA.
Faculty: Robert A. Figlin
Category: Biologic Therapy
Keywords: Clinical trials: Phase I, Colorectal cancer: other, Esophageal cancer, Lung cancer: non-small-cell, Prostate cancer
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News